Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps

Raul D. Santos, Luca Valenti, Stefano Romeo

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Non-alcoholic fatty liver disease (NAFLD) is highly prevalent and includes a spectrum of abnormalities ranging from steatosis to cirrhosis. In this review, we address recent evidence and limitations of studies that evaluated the association of NAFLD with atherosclerotic cardiovascular disease. NAFLD is considered an ectopic fat deposit associated with metabolic (insulin resistance, hyperglycemia and dyslipidemia), inflammatory, coagulation and blood pressure disturbances. Prospective studies have associated NAFLD presence and severity, particularly steatohepatitis and fibrosis, with an increased risk of cardiovascular disease. However, these studies are limited by heterogeneity concerning NAFLD diagnostic criteria and disease severity stratification, as well as by the presence of confounding factors. In addition, genetic variants predisposing to NAFLD, such as the PNPLA3 I148M mutation, were not consistently associated with an increased risk of cardiovascular events. Therefore, currently, it is not possible to prove a causal relation between NAFLD and cardiovascular disease. Furthermore, there is presently no evidence that NAFLD diagnosis can be used as a tool to improve cardiovascular risk stratification and modify treatment. Specific treatments for NAFLD are being developed and must be tested prospectively in adequately designed trials to determine the potential of reducing both hepatic and cardiovascular diseases and to prove whether NAFLD is indeed a cause of atherosclerosis.

Original languageEnglish
Pages (from-to)110-120
Number of pages11
JournalAtherosclerosis
Volume282
DOIs
Publication statusPublished - Mar 1 2019

Fingerprint

Cardiovascular Diseases
Fibrosis
Non-alcoholic Fatty Liver Disease
Fatty Liver
Dyslipidemias
Hyperglycemia
Insulin Resistance
Atherosclerosis
Fats
Prospective Studies
Blood Pressure
Mutation
Liver

Keywords

  • Atherosclerosis
  • Diabetes
  • Genetics
  • Hepatic steatosis
  • Non-alcoholic fatty liver disease
  • Obesity
  • Risk stratification

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. / Santos, Raul D.; Valenti, Luca; Romeo, Stefano.

In: Atherosclerosis, Vol. 282, 01.03.2019, p. 110-120.

Research output: Contribution to journalReview article

@article{3f57c726f1344f06855ca4d97c6e4805,
title = "Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps",
abstract = "Non-alcoholic fatty liver disease (NAFLD) is highly prevalent and includes a spectrum of abnormalities ranging from steatosis to cirrhosis. In this review, we address recent evidence and limitations of studies that evaluated the association of NAFLD with atherosclerotic cardiovascular disease. NAFLD is considered an ectopic fat deposit associated with metabolic (insulin resistance, hyperglycemia and dyslipidemia), inflammatory, coagulation and blood pressure disturbances. Prospective studies have associated NAFLD presence and severity, particularly steatohepatitis and fibrosis, with an increased risk of cardiovascular disease. However, these studies are limited by heterogeneity concerning NAFLD diagnostic criteria and disease severity stratification, as well as by the presence of confounding factors. In addition, genetic variants predisposing to NAFLD, such as the PNPLA3 I148M mutation, were not consistently associated with an increased risk of cardiovascular events. Therefore, currently, it is not possible to prove a causal relation between NAFLD and cardiovascular disease. Furthermore, there is presently no evidence that NAFLD diagnosis can be used as a tool to improve cardiovascular risk stratification and modify treatment. Specific treatments for NAFLD are being developed and must be tested prospectively in adequately designed trials to determine the potential of reducing both hepatic and cardiovascular diseases and to prove whether NAFLD is indeed a cause of atherosclerosis.",
keywords = "Atherosclerosis, Diabetes, Genetics, Hepatic steatosis, Non-alcoholic fatty liver disease, Obesity, Risk stratification",
author = "Santos, {Raul D.} and Luca Valenti and Stefano Romeo",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.atherosclerosis.2019.01.029",
language = "English",
volume = "282",
pages = "110--120",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps

AU - Santos, Raul D.

AU - Valenti, Luca

AU - Romeo, Stefano

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Non-alcoholic fatty liver disease (NAFLD) is highly prevalent and includes a spectrum of abnormalities ranging from steatosis to cirrhosis. In this review, we address recent evidence and limitations of studies that evaluated the association of NAFLD with atherosclerotic cardiovascular disease. NAFLD is considered an ectopic fat deposit associated with metabolic (insulin resistance, hyperglycemia and dyslipidemia), inflammatory, coagulation and blood pressure disturbances. Prospective studies have associated NAFLD presence and severity, particularly steatohepatitis and fibrosis, with an increased risk of cardiovascular disease. However, these studies are limited by heterogeneity concerning NAFLD diagnostic criteria and disease severity stratification, as well as by the presence of confounding factors. In addition, genetic variants predisposing to NAFLD, such as the PNPLA3 I148M mutation, were not consistently associated with an increased risk of cardiovascular events. Therefore, currently, it is not possible to prove a causal relation between NAFLD and cardiovascular disease. Furthermore, there is presently no evidence that NAFLD diagnosis can be used as a tool to improve cardiovascular risk stratification and modify treatment. Specific treatments for NAFLD are being developed and must be tested prospectively in adequately designed trials to determine the potential of reducing both hepatic and cardiovascular diseases and to prove whether NAFLD is indeed a cause of atherosclerosis.

AB - Non-alcoholic fatty liver disease (NAFLD) is highly prevalent and includes a spectrum of abnormalities ranging from steatosis to cirrhosis. In this review, we address recent evidence and limitations of studies that evaluated the association of NAFLD with atherosclerotic cardiovascular disease. NAFLD is considered an ectopic fat deposit associated with metabolic (insulin resistance, hyperglycemia and dyslipidemia), inflammatory, coagulation and blood pressure disturbances. Prospective studies have associated NAFLD presence and severity, particularly steatohepatitis and fibrosis, with an increased risk of cardiovascular disease. However, these studies are limited by heterogeneity concerning NAFLD diagnostic criteria and disease severity stratification, as well as by the presence of confounding factors. In addition, genetic variants predisposing to NAFLD, such as the PNPLA3 I148M mutation, were not consistently associated with an increased risk of cardiovascular events. Therefore, currently, it is not possible to prove a causal relation between NAFLD and cardiovascular disease. Furthermore, there is presently no evidence that NAFLD diagnosis can be used as a tool to improve cardiovascular risk stratification and modify treatment. Specific treatments for NAFLD are being developed and must be tested prospectively in adequately designed trials to determine the potential of reducing both hepatic and cardiovascular diseases and to prove whether NAFLD is indeed a cause of atherosclerosis.

KW - Atherosclerosis

KW - Diabetes

KW - Genetics

KW - Hepatic steatosis

KW - Non-alcoholic fatty liver disease

KW - Obesity

KW - Risk stratification

UR - http://www.scopus.com/inward/record.url?scp=85060930778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060930778&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2019.01.029

DO - 10.1016/j.atherosclerosis.2019.01.029

M3 - Review article

C2 - 30731283

AN - SCOPUS:85060930778

VL - 282

SP - 110

EP - 120

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

ER -